Buy SYNVISC®
Showing all 2 results
-


SYNVISC ONE®
$ 359.00 Add To Cart-+

SYNVISC®
$ 349.00 Add To Cart-+Licensed orthopedic specialists, sports medicine physicians, rheumatologists, and medical buyers looking to buy Synvisc® can source premium viscosupplementation products through Direct Doctor Supply. Manufactured by Genzyme Biosurgery, a Sanofi subsidiary, Synvisc® and Synvisc-One® are intra-articular injections indicated for the treatment of knee osteoarthritis pain in adults who have not achieved adequate relief with conservative therapy and simple analgesics. Both are built on proprietary hylan G-F 20 technology to supplement synovial fluid viscoelasticity and improve joint lubrication and mobility. Synvisc® and Synvisc-One® are authorized across multiple international markets. Practitioners can browse the Direct Doctor Supply catalog or contact the support team to check for wholesale buying options.
Understanding Hylan G-F 20 — Why Synvisc®’s Active Substance Matters
Hylan G-F 20 is a proprietary cross-linked derivative of hyaluronan, a natural substance sourced from avian tissue. Compared with many conventional sodium hyaluronate formulations, its higher molecular weight and cross-linked structure provide enhanced viscosity and elasticity, allowing it to more closely replicate the properties of healthy synovial fluid [4][5].
Once delivered into the knee joint, hylan G-F 20 addresses the diminished viscoelasticity associated with osteoarthritis, improving lubrication and shock absorption while helping to reduce pain during movement and daily activity [1][4]. These characteristics underpin the consistent, reliable outcomes that practitioners who rely on Synvisc® gel injections have documented across decades of clinical use and published research [1][2].
Sanofi and Genzyme — Manufacturing Expertise Behind Every Synvisc® Syringe
Synvisc® was originally developed by Genzyme, a specialty biotherapeutics company recognized for its expertise in rare disease and orthopedic care. Sanofi, one of the largest global healthcare companies, acquired Genzyme in 2011, and Genzyme Biosurgery remains the legal manufacturer of record for Synvisc® under Sanofi’s global quality and regulatory systems [3][4].
Each Synvisc® syringe is produced under rigorous quality standards designed to maintain sterility, product consistency, and batch-to-batch reliability. For healthcare providers, this manufacturing heritage supports confidence in both product quality and supply chain integrity, qualities that align directly with Direct Doctor Supply’ commitment to sourcing only market-approved, professionally licensed injectable products [4][5].
Synvisc® Product Spotlight
Synvisc® (Hylan G-F 20, 16 mg/2 mL — Three-Injection Course)
Synvisc® 16 mg/2 mL is formulated for adults with symptomatic knee osteoarthritis whose pain has not been adequately controlled by conservative management. Each treatment course consists of three separate 2 mL intra-articular injections administered one week apart, delivering a total of 48 mg of hylan G-F 20 across the full regimen [3][4]. The staged Synvisc® dosage protocol allows clinicians to monitor patient response throughout the treatment period and supports structured follow-up within the practice setting [1][5].
Synvisc-One® (Hylan G-F 20, 48 mg/6 mL — Single Injection)
This formulation delivers the full 48 mg dose of hylan G-F 20 in a single 6 mL intra-articular injection, providing the full treatment course in a single clinic visit [3][4]. The Synvisc-One® dosage is particularly suited to patients who prefer fewer appointments without any change to the active substance. Clinical data for the Synvisc-One® injection report symptom relief lasting up to six months in many individuals, though treatment response varies and individual outcomes depend on patient and disease characteristics [1][2][4].
Synvisc® and Synvisc-One® — Two Formulations to Fit Your Practice
The Synvisc® portfolio offers two treatment presentations built on the same hylan G-F 20 technology, enabling clinicians to match therapy to patient preferences and clinic workflow without switching active substances [4][5]. The three-injection Synvisc® course suits practices that value staged treatment assessment and regular patient contact, while the single Synvisc-One® injection is designed for patients and settings where single-visit convenience is the priority. Together, these formulations give practitioners the flexibility to individualize treatment planning while maintaining confidence in an established viscosupplementation technology [1][3].
A Step-by-Step Guide to Synvisc® Injection Technique
Synvisc® injection procedures should be performed by qualified healthcare professionals using strict aseptic technique in line with the manufacturer’s Instructions for Use [4][5]. Before treatment, the knee should be assessed for joint effusion, with aspiration performed when clinically appropriate to improve patient comfort and optimize the intra-articular space [5].
Following skin preparation and patient positioning, the needle is advanced carefully into the joint space. Needle gauge selection should follow the guidance in the product IFU alongside the clinician’s judgment based on patient anatomy. Accurate injection in knees with Synvisc® supports effective product placement while reducing the risk of injection-site complications [4][5].
Synvisc® is administered as a single 2 mL intra-articular injection weekly for three consecutive weeks; Synvisc-One® is delivered as a single 6 mL injection in a single visit [3][4]. Patients are generally advised to avoid strenuous weight-bearing activity for approximately 48 hours after each injection, then gradually resume normal movement as directed by their treating clinician [4].
For reimbursement, the Synvisc® CPT code 20610 is commonly referenced for the large-joint injection procedure itself, while product-specific HCPCS J-codes should be verified against current payer policies for the hylan G-F 20 supply [3][4].
Who Benefits from Synvisc® Injections? Patient Selection and Indications
Synvisc® is indicated for adults with symptomatic knee osteoarthritis who continue to experience chronic knee pain, joint stiffness, and functional limitation despite exercise therapy, physical rehabilitation, lifestyle modification, and simple analgesics [3][5]. Synvisc® injections for chronic knee osteoarthritis provide a non-surgical pain treatment option for patients who are not yet surgical candidates or who wish to delay more invasive intervention.
Typical candidates for Synvisc® include those with confirmed moderate-to-severe knee OA whose conservative management has not delivered satisfactory symptom control, and who may benefit from intra-articular joint fluid supplementation to improve daily function [1][5]. Clinicians should evaluate symptom severity, radiographic findings, prior treatment response, activity level, and functional goals before recommending viscosupplementation therapy.
Synvisc® is contraindicated in patients with active joint infection or skin disease at the intended injection site, and in those with known hypersensitivity to hyaluronan products [4]. Clinicians should review the IFU for guidance on avian-protein sensitivity before treating patients who may be affected [4]. Individual treatment decisions should always account for patient comorbidities and clinical objectives.
What Distinguishes Synvisc® from Other Viscosupplementation Options
Synvisc® carries one of the longest-established clinical evidence records among viscosupplementation products, supported by decades of published research, post-market safety data, and accumulated practitioner experience [1][2]. This depth of evidence gives clinicians a reliable framework for evaluating expected outcomes, and studies have documented decreased pain and improved mobility across treatment courses [1][4].
Its dual-format portfolio also enables clinicians to tailor the injection schedule to individual clinical needs without switching brands or active substances. Whether the priority is regular clinical assessment across a three-injection course or single-visit convenience through Synvisc-One®, both options deliver the same hylan G-F 20 formulation [3][4]. For a purchasing practice, that single-brand flexibility also simplifies procurement and inventory: both presentations are sourced through the same supply channel and share the same handling and storage profile, so a clinic can stock for varied patient schedules without qualifying a second manufacturer.
Synvisc® vs ORTHOVISC®, EUFLEXXA®, and MONOVISC®
Synvisc® vs ORTHOVISC®
Synvisc® and ORTHOVISC® are both established viscosupplementation options for symptomatic knee osteoarthritis but differ in molecular composition and formulation approach. Synvisc® contains cross-linked, avian-derived hylan G-F 20, whereas ORTHOVISC® contains ultra-high-molecular-weight, non-cross-linked sodium hyaluronate [1][4]. Clinicians may select one over the other based on patient characteristics, injection schedule preference, and clinical experience. Practices offering multiple viscosupplementation options may choose to buy ORTHOVISC® to broaden treatment options while maintaining flexibility across diverse patient populations.
Synvisc® vs EUFLEXXA®
Both Synvisc® and EUFLEXXA® are indicated for patients with knee OA who have not responded adequately to conservative treatment, yet they differ meaningfully in their source materials and production processes. Synvisc® uses cross-linked hylan G-F 20 derived from avian tissue, while EUFLEXXA® contains bioengineered, non-avian sodium hyaluronate produced through bacterial fermentation [1][4]. When evaluating Euflexxa vs Synvisc®, practitioners typically weigh formulation differences alongside patient sensitivity profiles, injection schedule, and the depth of long-term clinical evidence. Licensed professionals can buy EUFLEXXA® on Direct Doctor Supply for practices that maintain multiple viscosupplementation options.
Synvisc® vs MONOVISC®
Synvisc-One® and MONOVISC® both provide single-visit viscosupplementation for knee osteoarthritis but differ in their hyaluronic acid formulations, molecular structures, and manufacturing technologies [1][4]. When assessing Monovisc vs Synvisc®, clinicians commonly consider previous treatment response, patient convenience, and published clinical data to guide product selection. Practices looking to expand their single-injection viscosupplementation offering can buy MONOVISC® through Direct Doctor Supply. Clinicians comparing longer-acting single-injection options sometimes also weigh Durolane vs Synvisc®, since Durolane offers an alternative single-injection profile.
Direct Doctor Supply has supplied professional-grade injectable products to licensed healthcare professionals since 2014, offering wholesale deals, reliable shipping, guaranteed delivery, and a dedicated support team for ongoing sourcing and documentation assistance. Practitioners looking to buy Synvisc® online, or to purchase Synvisc® online for a single clinic, can contact the Direct Doctor Supply support team directly for product availability, pricing guidance, and assistance with wholesale purchasing options. Practices that manage broader treatment portfolios may also buy hyaluronic acid dermal fillers through the same procurement platform.
Synvisc® Side Effects and Safety Considerations for Practitioners
Synvisc® and Synvisc-One® are generally well-tolerated when administered according to the manufacturer’s Instructions for Use [4][5]. Among the commonly reported adverse events, the most frequent side effects of Synvisc® are local and typically resolve with conservative management [1][4]:
- Temporary injection-site pain
- Localized swelling
- Warmth at the injection site
- Joint effusion
Less commonly, patients may experience an acute local joint reaction, sometimes referred to as a pseudoseptic reaction, which requires prompt clinical evaluation to exclude septic arthritis [4]. Synvisc® is contraindicated in patients with active joint infection, skin disease at the intended injection site, or known hypersensitivity to hyaluronan products. Clinicians should consult the IFU regarding avian protein sensitivity before treatment in patients at risk [4].
Weight gain is not recognized as a direct adverse effect of hylan G-F 20, and clinicians should continue to encourage appropriate lifestyle measures and exercise therapy as part of comprehensive osteoarthritis management [4][5].
Regulatory Licenses — Synvisc® Approvals Across Key Markets
Synvisc® received U.S. FDA Premarket Approval (PMA P940015) in 1997 for treating pain associated with knee osteoarthritis in patients who have not responded adequately to conservative therapy and simple analgesics [3]. This FDA approval under PMA reflects the clinical and regulatory standards Synvisc® has met as a Class III medical device in the United States.
Synvisc® and Synvisc-One® are authorized for use and widely distributed across multiple international markets, including the European Union, Canada, and Australia, under their respective regulatory frameworks [3][4]. Direct Doctor Supply supplies only fully licensed, market-approved viscosupplementation products sourced through verified distribution channels, with regulatory compliance forming a core part of the platform’s quality promise to practitioners.
Synvisc® Availability — Global Reach and Supply Consistency
With approvals spanning the United States, Europe, Canada, and Australia, Synvisc® supports established knee OA treatment pathways worldwide, and its long-standing distribution footprint has made it a dependable presence in orthopedic practice [3][4]. Direct Doctor Supply sources licensed Synvisc® products through established supply channels that prioritize authenticity, reliable inventory levels, and transparent procurement for licensed practitioners. When buying online through Direct Doctor Supply, practitioners work with a platform that has maintained consistent Synvisc® stock since 2014.
Practitioners looking to buy orthopedic injections from a single supplier can streamline procurement by consolidating viscosupplementation products into a single coordinated ordering process. Clinics that also buy dermal fillers alongside orthopedic injectables can manage both categories through the same Direct Doctor Supply procurement platform.
Buy Synvisc® Wholesale Through Direct Doctor Supply
Direct Doctor Supply supplies Synvisc® and Synvisc-One® to qualified, licensed practitioners and clinic procurement teams only. When you buy Synvisc® wholesale, sourcing from a supplier with verifiable purity documentation, lot traceability, and market-approved distribution protects both patient safety and regulatory standing, so confirm these are in place with any order.
The Direct Doctor Supply catalog offers competitive wholesale pricing and temperature-appropriate shipping to preserve product integrity in transit, and the support team can confirm current availability and lead times.
Frequently Asked Questions
What is Synvisc® used for?
Synvisc® is indicated for treating pain associated with knee osteoarthritis in adults who have not responded adequately to conservative therapy and simple analgesics [3][5]. Supplementing the joint with hylan G-F 20 helps restore synovial fluid viscoelasticity, improving lubrication, cushioning, and overall joint function.
What is Synvisc® made of?
Synvisc® contains hylan G-F 20, a cross-linked derivative of hyaluronan obtained from avian tissue. Its higher molecular weight and cross-linked structure confer viscoelastic properties that more closely resemble those of healthy synovial fluid than many standard sodium hyaluronate formulations [4][5]. Hylan G-F 20 is effectively the Synvisc® generic name, describing the active substance shared by both presentations.
What is the difference between Synvisc® and Synvisc-One®?
Synvisc® is administered as three weekly 2 mL intra-articular injections, while the Synvisc-One® injection delivers the full 48 mg dose in a single 6 mL visit [3][4]. Both contain hylan G-F 20 but offer different administration schedules to accommodate patient and clinic preferences.
How is Synvisc® administered?
Synvisc® is administered by intra-articular injection using aseptic technique following appropriate patient assessment [4][5]. Joint effusion should be aspirated, if clinically indicated, before injection. The standard Synvisc® regimen consists of three weekly injections, while Synvisc-One® is administered in a single session.
How long does pain relief with Synvisc® last?
Many patients experience meaningful symptom improvement for up to six months following a treatment course, though individual results vary [1][2][4]. Repeat treatment may be considered after clinical reassessment in patients who continue to meet the criteria for viscosupplementation.
What are the side effects of Synvisc®?
The most commonly reported adverse events include temporary injection-site pain, swelling, warmth, and joint effusion, which typically resolve with conservative care [1][4]. Rare inflammatory reactions may occur and should be evaluated promptly. The product should not be used in patients with active joint infection, skin disease at the intended injection site, or known hypersensitivity to hyaluronan products; clinicians should consult the IFU for guidance on avian-protein sensitivity [4].
Can Synvisc® be used instead of knee replacement surgery?
Synvisc® is a non-surgical knee pain treatment option that may help appropriately selected patients manage symptoms and delay the need for more invasive interventions [3][4]. It is not intended as a substitute for knee replacement when surgical intervention is clinically indicated. For knee replacement patients whose surgery is already scheduled, treatment decisions should reflect each patient’s overall clinical picture and goals.
How does Synvisc® compare with ORTHOVISC® and EUFLEXXA®?
All three products are viscosupplementation options for knee osteoarthritis but differ in hyaluronic acid source, molecular structure, and injection schedule [1][4]. EUFLEXXA® uses non-avian, bioengineered sodium hyaluronate, while ORTHOVISC® features ultra-high-molecular-weight, non-cross-linked HA. Product selection should be guided by patient characteristics, clinical judgment, and treatment objectives.
Looking to source Synvisc® products? Direct Doctor Supply can help
Licensed practitioners can explore the Direct Doctor Supply catalog to find Synvisc® and Synvisc-One® products, backed by a platform trusted since 2014 for consistent stock, wholesale purchasing support, and guaranteed delivery. The Direct Doctor Supply support team is available to assist with sourcing inquiries, Synvisc® NDC number references, and product documentation.
Citations and Resources about Synvisc®
[1] Pavelka K, Uebelhart D. Efficacy evaluation of highly purified intra-articular hyaluronic acid (Sinovial®) vs hylan G-F20 (Synvisc®) in the treatment of symptomatic knee osteoarthritis. A double-blind, controlled, randomized, parallel-group non-inferiority study. Osteoarthritis Cartilage. 2011;19(11):1294-1300. https://pubmed.ncbi.nlm.nih.gov/21875678/
[2] Clarke S, Lock V, Duddy J, Sharif M, Newman JH, Kirwan JR. Intra-articular hylan G-F 20 (Synvisc®) in the management of patellofemoral osteoarthritis of the knee (POAK). Knee. 2005;12(1):57-62. https://pubmed.ncbi.nlm.nih.gov/15664879/
[3] U.S. Food and Drug Administration. Premarket Approval (PMA) SYNVISC ONE, P940015. FDA. Updated 2026. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?ID=P940015S012
[4] Sanofi. Synvisc® (HYLAN G-F 20) Prescribing Information. https://products.sanofi.us/synvisc/synvisc.html
[5] Sanofi. Dosing and Administration for Synvisc® (hylan G-F 20) and SYNVISC-ONE® (hylan G-F 20). https://pro.campus.sanofi/us/products/synviscone/dosing-and-administration
All content on this website is intended for informational purposes and does not constitute medical advice.
Content prepared by Direct Doctor Supply’s editorial team.
Sourcing and accuracy for this page follow our Editorial Policy: claims are cross-checked against clinical literature, regulatory filings, and manufacturer specifications before anything is published.